Want to see JP:7777 full AI Analyst Report?
Top Page
3-D Matrix
(7777)
Select Model
Select Model
Rating:59Neutral
Price Target:
¥322.00
▼(-2.13% Downside)
Action:Reiterated
Date:06/13/26
The score is driven mainly by improving fundamentals (profitability turnaround and reduced leverage), partially offset by weak cash-flow conversion and a multi-year history of cash burn. Technicals also weigh on the score due to a pronounced downtrend and negative momentum, while valuation is a relative positive given the modest P/E.
Positive Factors
Revenue Growth
Sustained, accelerating revenue growth indicates expanding product adoption and market penetration in medical devices. Over 2-6 months this supports higher operating leverage, improved pricing power, and a larger addressable base for cross-selling and scaling fixed-cost absorption.
Negative Factors
Weak Cash Conversion
Low conversion of reported profits into cash suggests earnings quality issues, working-capital pressure, or one-time accounting effects. Over months this limits ability to self-fund growth, raises liquidity risk, and makes the company vulnerable if profitability weakens.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained, accelerating revenue growth indicates expanding product adoption and market penetration in medical devices. Over 2-6 months this supports higher operating leverage, improved pricing power, and a larger addressable base for cross-selling and scaling fixed-cost absorption.
Read all positive factors
3-D Matrix (7777) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥45.56B
Dividend YieldN/A
Average Volume (3M)4.78M
Price to Earnings (P/E)10.4
Beta (1Y)1.72
Revenue Growth57.00%
EPS GrowthN/A
CountryJP
Employees129
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)34.88
Shares Outstanding127,981,480
10 Day Avg. Volume2,399,770
30 Day Avg. Volume4,782,760
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)9.04
Price to Sales (P/S)5.65
P/FCF Ratio166.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
3-D Matrix Business Overview & Revenue Model
Company Description
3-D Matrix, Ltd. specializes in pioneering self-assembling peptide technology. Its flagship product, PuraMatrix, is an innovative self-assembling peptide hydrogel with diverse applications across medical fields, including regenerative medicine, ce...
3-D Matrix Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
67
Positive
Cash Flow
41
Neutral
| Breakdown | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.89B | 6.93B | 4.59B | 2.31B | 1.51B |
| Gross Profit | 8.57B | 4.42B | 3.09B | 1.29B | 661.01M |
| EBITDA | 4.17B | -2.40B | 59.13M | 715.00M | 843.00M |
| Net Income | 4.16B | -2.50B | -255.50M | -2.45B | -1.89B |
Balance Sheet | |||||
| Total Assets | 9.80B | 6.51B | 5.89B | 5.83B | 5.61B |
| Cash, Cash Equivalents and Short-Term Investments | 2.83B | 1.58B | 1.36B | 1.17B | 2.85B |
| Total Debt | 600.00M | 2.94B | 4.17B | 4.37B | 3.67B |
| Total Liabilities | 3.00B | 4.30B | 5.53B | 5.30B | 4.15B |
| Stockholders Equity | 6.80B | 2.22B | 353.31M | 524.77M | 1.46B |
Cash Flow | |||||
| Free Cash Flow | 368.89M | -1.73B | -1.90B | -4.60B | -2.92B |
| Operating Cash Flow | 396.85M | -1.71B | -1.90B | -4.59B | -2.90B |
| Investing Cash Flow | -42.48M | -33.30M | -29.76M | -81.50M | -79.86M |
| Financing Cash Flow | 786.49M | 2.01B | 2.06B | 2.96B | 4.66B |
3-D Matrix Technical Analysis
Negative
329.00
Price Trends
350.34
Positive
410.87
Negative
422.38
Negative
Market Momentum
3.13
Negative
49.26
Neutral
22.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7777, the sentiment is Negative. The current price of 329 is below the 20-day moving average (MA) of 351.85, below the 50-day MA of 350.34, and below the 200-day MA of 422.38, indicating a neutral trend. The MACD of 3.13 indicates Negative momentum. The RSI at 49.26 is Neutral, neither overbought nor oversold. The STOCH value of 22.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7777.
3-D Matrix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | ¥17.78B | 11.98 | ― | 3.02% | 20.88% | 44.61% | |
63 Neutral | ¥250.42B | 17.77 | ― | 1.92% | 1.43% | 1.86% | |
62 Neutral | ¥9.00B | 10.64 | ― | 1.89% | 9.02% | 8.88% | |
59 Neutral | ¥45.56B | 10.41 | 1.45% | ― | 57.00% | ― | |
57 Neutral | ¥77.48B | 21.40 | ― | 2.28% | 2.94% | 57.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥194.17B | 21.08 | 0.33% | 3.73% | 3.04% | -19.26% |
* Healthcare Sector Average
JP:7777
3-D Matrix
362.00
148.00
69.16%
JP:6523
PHC Holdings Corp.
1,527.00
563.08
58.42%
JP:4549
Eiken Chemical Co., Ltd.
2,307.00
-113.97
-4.71%
JP:6678
Techno Medica Co., Ltd.
2,118.00
188.32
9.76%
JP:6849
Nihon Kohden Corporation
1,487.00
-120.64
-7.50%
JP:7963
Koken Ltd.
1,820.00
56.78
3.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.